IMVT

Immunovant, Inc.

Healthcare
Biotechnology
$7.71B market cap

Forecast run · Sep 15, 2026Upside rank 1090 of 3,136

Model Signal

ForecastQ Daily Probabilities

42.6%

32.6%

18.6%

Analyst Consensus

Recommendation2.26/5 Buy

Last price$37.36

Price target$40.00

Implied move+7.1%

Analysts23

ForecastQ Portfolios

IMVT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.